Skip to main content
Clinical Trials/NCT06060444
NCT06060444
Completed
N/A

Evaluating a Telemedicine Neurological Consult Program for Drug-Induced Movement Disorders Using the RE-AIM Framework

University of Vermont1 site in 1 country28 target enrollmentApril 26, 2022

Overview

Phase
N/A
Intervention
Not specified
Conditions
Drug-Induced Movement Disorder
Sponsor
University of Vermont
Enrollment
28
Locations
1
Primary Endpoint
Effectiveness; Client Satisfaction Questionnaire-8 (CSQ-8)
Status
Completed
Last Updated
last year

Overview

Brief Summary

In this pilot study, the investigators will evaluate care delivery via telemedicine to individuals with drug-induced movement disorders (DIMDs). DIMDs can be disabling, and prevention is important; but these disorders are often under-reported, under-recognized and poorly managed. Interprofessional telemedicine for movement disorders is feasible and may provide similar care as in-person visits; however, the majority of studies to date have shown benefit in Parkinson's disease and further validation in other movement disorders is necessary.

In this randomized controlled trial the aim is to study the acceptability, feasibility, and patient and clinician outcomes when a neurological consultation is provided for patients with DIMDs either in-person or through telemedicine. The investigators will apply the evaluation framework RE-AIM (Reach and Effectiveness, Adoption, Implementation, and Maintenance) to comprehensively assess the factors that may impact study success and program implementation. Mixed methods will be implemented to gather outcome data from mental health clinicians that refer patients and the patient participants.

Registry
clinicaltrials.gov
Start Date
April 26, 2022
End Date
October 31, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Emily Houston

Principal Investigator

University of Vermont

Eligibility Criteria

Inclusion Criteria

  • 18 years or older
  • Willing and able to provide consent
  • Willing to have their Mental Health Clinician (MHC) share sensitive clinical information with the Neurology team
  • Able to travel to Neurology clinic
  • Have connectivity to Zoom using wi-fi or cellular data, either at home or a comfortable and private setting (such as MHC office)

Exclusion Criteria

  • Currently hospitalized
  • Neurologist determines patient requires care outside of the scope of the study

Outcomes

Primary Outcomes

Effectiveness; Client Satisfaction Questionnaire-8 (CSQ-8)

Time Frame: 12 months

How satisfied are patients with the program

Secondary Outcomes

  • Effectiveness; referral forms and visit notes(12 months)
  • Effectiveness; visit notes(12 months)
  • Effectiveness; PROMIS 29+2 V2.1(12 months)
  • Effectiveness; MHC survey and Qualitative Interviews(12 months)

Study Sites (1)

Loading locations...

Similar Trials